Hereditary Spherocytosis Clinical Trials 2026 — Find Recruiting Studies

About Hereditary Spherocytosis

Hereditary spherocytosis is the most common inherited hemolytic anemia in Northern Europeans, caused by mutations in genes encoding red blood cell membrane skeletal proteins including ankyrin-1 (ANK1), alpha-spectrin (SPTA1), beta-spectrin (SPTB), and band 3 (SLC4A1), leading to defective membrane anchorage and progressive loss of membrane surface area. The resulting spherocytic red cells are osmotically fragile and preferentially trapped and destroyed in the spleen, causing chronic hemolytic anemia of variable severity, splenomegaly, and gallstone formation. Splenectomy effectively eliminates hemolysis but carries lifelong risks of sepsis from encapsulated organisms.

Common Clinical Features

Chronic hemolytic anemia with variable severity (mild to severe) Neonatal jaundice requiring phototherapy Splenomegaly often detectable by physical examination Pallor and fatigue proportional to degree of anemia Cholelithiasis with pigmented gallstones Aplastic crisis precipitated by parvovirus B19 infection Osmotic fragility on eosin-5-maleimide (EMA) binding test Occasional leg ulcers and extramedullary hematopoiesis in severe cases

Clinical Trial Eligibility Tips

What to know before applying to Hereditary Spherocytosis trials.

Diagnosis confirmation by EMA binding test, osmotic fragility test, or peripheral blood smear showing spherocytes, along with negative direct antiglobulin test, is required to exclude autoimmune hemolytic anemia in trial screening.

Splenectomy status is a major eligibility variable; post-splenectomy patients have near-normal hemoglobin but residual laboratory abnormalities; pre-splenectomy patients may qualify for trials evaluating alternatives to splenectomy.

Severity classification (mild, moderate, severe based on hemoglobin and bilirubin levels) and any identified gene mutation help match patients to appropriate investigational studies.